Modern immunological criteria for a stratification of risk groups for precursor B cell acute lymphoblastic leukemia in children

Background. Modern therapy programs allow achieving high survival rates in children with acute lymphoblastic leukemia (ALL). However, there is a group of patients in whom a relapse occurs, which makes it necessary to search for optimal tools for monitoring remission and the earliest detection of ALL...

Full description

Bibliographic Details
Main Authors: Meri A. Shervashidze, Timur T. Valiev, Natalia A. Batmanova, Nikolai N. Tupitsyn, Irina N. Serebryakova
Format: Article
Language:Russian
Published: IP Habib O.N. 2020-05-01
Series:Современная онкология
Subjects:
Online Access:https://modernonco.orscience.ru/1815-1434/article/viewFile/34006/21716
_version_ 1818287733622177792
author Meri A. Shervashidze
Timur T. Valiev
Natalia A. Batmanova
Nikolai N. Tupitsyn
Irina N. Serebryakova
author_facet Meri A. Shervashidze
Timur T. Valiev
Natalia A. Batmanova
Nikolai N. Tupitsyn
Irina N. Serebryakova
author_sort Meri A. Shervashidze
collection DOAJ
description Background. Modern therapy programs allow achieving high survival rates in children with acute lymphoblastic leukemia (ALL). However, there is a group of patients in whom a relapse occurs, which makes it necessary to search for optimal tools for monitoring remission and the earliest detection of ALL relapse. According to clinical and immunological studies, assessment of minimal residual disease (MRD) levels is one of the leading criteria for response to treatment and can be the basis for risk-stratified therapy. Aim. Assessment of MRD levels on the 15th day of induction as the main parameter for stratification of patients into prognostic risk groups and the impact of MOB levels on patient survival. Materials and methods. The study included 117 children with a newly diagnosed precursor B-cell ALL. All patients were given an induction course according to the BFM ALL IC 2009 protocol. MRD levels were determined by flow cytometry. Results. Given the MRD based stratification, a truly standard risk group was identified, the survival rate of which reached 100%. Conclusions. The use of MRD as the main tool for the risk of adapted therapy made it possible to improve survival in patients of the standard risk group, as well as to optimize therapy for high and medium risk groups in the future.
first_indexed 2024-12-13T01:45:11Z
format Article
id doaj.art-79e213ecc00840e39b10e161994306f2
institution Directory Open Access Journal
issn 1815-1434
1815-1442
language Russian
last_indexed 2024-12-13T01:45:11Z
publishDate 2020-05-01
publisher IP Habib O.N.
record_format Article
series Современная онкология
spelling doaj.art-79e213ecc00840e39b10e161994306f22022-12-22T00:03:39ZrusIP Habib O.N.Современная онкология1815-14341815-14422020-05-01214222610.26442/18151434.2019.4.19074530677Modern immunological criteria for a stratification of risk groups for precursor B cell acute lymphoblastic leukemia in childrenMeri A. Shervashidze0Timur T. Valiev1Natalia A. Batmanova2Nikolai N. Tupitsyn3Irina N. Serebryakova4Blokhin National Medical Research Center of OncologyBlokhin National Medical Research Center of OncologyBlokhin National Medical Research Center of OncologyBlokhin National Medical Research Center of OncologyBlokhin National Medical Research Center of OncologyBackground. Modern therapy programs allow achieving high survival rates in children with acute lymphoblastic leukemia (ALL). However, there is a group of patients in whom a relapse occurs, which makes it necessary to search for optimal tools for monitoring remission and the earliest detection of ALL relapse. According to clinical and immunological studies, assessment of minimal residual disease (MRD) levels is one of the leading criteria for response to treatment and can be the basis for risk-stratified therapy. Aim. Assessment of MRD levels on the 15th day of induction as the main parameter for stratification of patients into prognostic risk groups and the impact of MOB levels on patient survival. Materials and methods. The study included 117 children with a newly diagnosed precursor B-cell ALL. All patients were given an induction course according to the BFM ALL IC 2009 protocol. MRD levels were determined by flow cytometry. Results. Given the MRD based stratification, a truly standard risk group was identified, the survival rate of which reached 100%. Conclusions. The use of MRD as the main tool for the risk of adapted therapy made it possible to improve survival in patients of the standard risk group, as well as to optimize therapy for high and medium risk groups in the future.https://modernonco.orscience.ru/1815-1434/article/viewFile/34006/21716acute lymphoblastic leukemiaminimal residual diseasechildrenrisk-adopted therapychildren
spellingShingle Meri A. Shervashidze
Timur T. Valiev
Natalia A. Batmanova
Nikolai N. Tupitsyn
Irina N. Serebryakova
Modern immunological criteria for a stratification of risk groups for precursor B cell acute lymphoblastic leukemia in children
Современная онкология
acute lymphoblastic leukemia
minimal residual disease
children
risk-adopted therapy
children
title Modern immunological criteria for a stratification of risk groups for precursor B cell acute lymphoblastic leukemia in children
title_full Modern immunological criteria for a stratification of risk groups for precursor B cell acute lymphoblastic leukemia in children
title_fullStr Modern immunological criteria for a stratification of risk groups for precursor B cell acute lymphoblastic leukemia in children
title_full_unstemmed Modern immunological criteria for a stratification of risk groups for precursor B cell acute lymphoblastic leukemia in children
title_short Modern immunological criteria for a stratification of risk groups for precursor B cell acute lymphoblastic leukemia in children
title_sort modern immunological criteria for a stratification of risk groups for precursor b cell acute lymphoblastic leukemia in children
topic acute lymphoblastic leukemia
minimal residual disease
children
risk-adopted therapy
children
url https://modernonco.orscience.ru/1815-1434/article/viewFile/34006/21716
work_keys_str_mv AT meriashervashidze modernimmunologicalcriteriaforastratificationofriskgroupsforprecursorbcellacutelymphoblasticleukemiainchildren
AT timurtvaliev modernimmunologicalcriteriaforastratificationofriskgroupsforprecursorbcellacutelymphoblasticleukemiainchildren
AT nataliaabatmanova modernimmunologicalcriteriaforastratificationofriskgroupsforprecursorbcellacutelymphoblasticleukemiainchildren
AT nikolaintupitsyn modernimmunologicalcriteriaforastratificationofriskgroupsforprecursorbcellacutelymphoblasticleukemiainchildren
AT irinanserebryakova modernimmunologicalcriteriaforastratificationofriskgroupsforprecursorbcellacutelymphoblasticleukemiainchildren